Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06875609 · ClinicalTrials.gov registry record
ctDNA in Cutaneous Squamous Cell Carcinoma
A clinical trial of Cutaneous Squamous Cell Carcinoma, sponsored by Massachusetts Eye and Ear Infirmary.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT06875609 is a study of Cutaneous Squamous Cell Carcinoma that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 60 participants, below the 89-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06875609, a study of Cutaneous Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood and Tissue Collection
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-24 |
| Est. Completion | 2029-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06875609
The ClinicalTrials.gov registry entry for NCT06875609 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (33% lower). The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Blood and Tissue Collection is the first listed.
NCT06875609 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06875609 about?
NCT06875609 is a clinical study titled "ctDNA in Cutaneous Squamous Cell Carcinoma". The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.
What is the current status of trial NCT06875609?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2025-03-24. Estimated completion is 2029-04-30.
What conditions does trial NCT06875609 study?
This clinical trial studies the following conditions: Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06875609?
The interventions under investigation include: Blood and Tissue Collection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06875609?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06875609 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
RECRUITING · NA
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
RECRUITING · Phase 1
-
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.